Biosimilars sales were $201.5 million, up 7% driven by Benepali, with sales of $125 million, up 16%. LEQEMBI global in-market sales in the quarter were approximately $87 million, including U.S.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback